ARTICLE | Financial News

Israeli rare disease play Bio Blast files for IPO

February 11, 2014 2:21 AM UTC

Bio Blast Pharma Ltd. (Tel Aviv, Israel) filed to raise up to $37.5 million in an IPO on NASDAQ underwritten by Aegis. Bio Blast's Cabaletta is in the Phase II HOPEMD trial to treat oculopharyngeal muscular dystrophy (OPMD). Cabaletta is an IV formulation of trehalose that Bio Blast said enables therapeutic doses of the compound to reach muscles. Trehalose is a disaccharide that prevents pathological aggregation of proteins in cells. ...